AI Market Mood: Stock Dashboard
PRTA
Fundamental
Technical:
Latest News:
Bristol Myers Squibb licenses Prothena's PRX019 for $80 million - Investing.com neutral
PRTA
Summary: Prothena Corporation plc (NASDAQ:PRTA) has entered into a licensing agreement with Bristol Myers Squibb for an investigational drug, PRX019, for neurodegenerative diseases. Prothena will receive an $80 million upfront payment and could get up to $617.5 million in milestone payments, along with royalties on net sales. The FDA has cleared the IND application for PRX019, and Prothena plans to start a Phase 1 clinical trial by the end of 2024, aiming to address diseases caused by protein dysregulation.
Full articleProthena Reports First Quarter 2024 Financial Results and Business Highlights | Placera neutral
PRTA
Summary: Prothena Corporation plc reported financial results for the first quarter of 2024 and provided business highlights including progress in clinical programs for various neurodegenerative diseases and rare peripheral amyloid diseases, and announced upcoming clinical milestones. They also shared their first quarter financial results.
Full articleProthena Reports First Quarter 2024 Financial Results and Business Highlights neutral
PRTA
Summary: Prothena Corporation plc (NASDAQ:PRTA) reported financial results for the first quarter of 2024, including a net loss of $72.2 million. The company highlighted ongoing clinical programs and upcoming milestones in Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, and rare peripheral amyloid diseases portfolio. Prothena also provided insights into its financial guidance for the year 2024.
Full articleProthena to Participate in 2023 Bank of America Healthcare Conference neutral
PRTA
Summary: Prothena Corporation plc announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference. A live webcast will be available through the investor relations section of the Company's website.
Full articleProthena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program ... very bullish
PRTA
Summary: Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1. Prothena announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005 and will pay Prothena $80 million. Phase 1 study with PRX005 has initiated.
Full article